Subject: PR tied to Canada
progress as expected.

PR today:
https://www.esperion.com/news-...

Up next?
1. partnership for Canada, Australia, and Israel.
2. refinancing of Notes due in 2025
3. investor day/news on additional indications (Liver, Kidney, Oncology) that could significantly expand patent life.
4. Otsuka milestones
5. DSE milestones
6. DSE taking over mfr production of pills in 2025 (reducing costs)
7. DS (non-EU) royalties ramping in South America, Asian countries, etc...
8. Esperion overall US partnership or acquisition?

Dreamer